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Abstract
Background—The organic anion transporting polypeptides (OATP)/SLCO family represents an
important class of hepatic drug uptake transporters that mediate the sodium independent transport
of a diverse range of amphipathic organic compounds, including the protease inhibitors. The
SLCO1B1 521T>C (rs4149056) single nucleotide polymorphism (SNP) has been consistently
associated with reduced transport activity in vivo, and we previously showed an association of this
polymorphism with lopinavir plasma concentrations. The aim of this study was to develop a
population pharmacokinetic (PK) model to quantify the impact of 521T>C.
Methods—A population PK analysis was performed with 594 plasma samples from 375 patients
receiving lopinavir/ritonavir. Non-linear mixed effects modelling was applied to explore the
effects of SLCO1B1 521T>C and patient demographics. Simulations of the lopinavir
concentration profile were performed with different dosing regimens considering the different
alleles.
Results—A one-compartment model with first-order absorption best described the data.
Population clearance was 5.67 L/h with inter-patient variability of 37%. Body weight was the only
demographic factor influencing clearance, which increased 0.5 L/h for every 10 kg increase.
Homozygosity for the C allele was associated with a 37% lower clearance, and 14% for
heterozygosity, which were statistically significant.
Conclusion—These data show an association between SLCO1B1 521T>C and lopinavir
clearance. The association is likely to be mediated through reduced uptake by hepatocytes leading
to higher plasma concentrations of lopinavir. Further studies are now required to confirm the
association and to assess the influence of other polymorphisms in the SLCO family on lopinavir
PK.
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Introduction
Organic anion transporting polypeptides (OATP), coded for by the SLCO genes, are a
family of solute carrier membrane transport proteins which influx numerous endogenous and
xenobiotic compounds. Many of the OATPs (of which there are currently 13 known
members) have wide substrate specificity and are expressed ubiquitously [1]. The main
OATPs associated with hepatic drug uptake are OATP1B1 (OATP-C) [2, 3] and OATP1B3,
which are localized on the basolateral membrane of hepatocytes. The SLCO1B1 gene
encoding OATP1B1 is polymorphic, which may affect OATP1B1 transport function and,
consequently, the hepatic uptake and plasma concentrations of OATP1B1 substrates.
SLCO1B1 polymorphisms may also modify drug-drug interactions mediated by OATP1B1
[4]. Many drugs, such as statins, and more recently HIV protease inhibitors (PIs) have been
identified as OATP1B1 substrates [5, 6].
HIV PIs have marked inter-individual variability in plasma concentrations and therapeutic
drug monitoring (TDM) can be considered for optimizing therapy in some clinical
situations. Achieving target plasma PI and non-nucleoside reverse transcriptase inhibitor
concentrations is vital for HIV therapy as suboptimal concentrations can lead to the
emergence of drug resistance [7-9], and high concentrations may lead to toxicity [8, 10].
Lopinavir is currently one of the most widely used PIs. Lopinavir is mainly metabolized by
CYP3A enzymes and is also a substrate for the efflux transporters ABCB1, ABCC1 and
ABCC2, which contribute to its low and variable oral bioavailability. To overcome these
pharmacokinetic limitations and obtain adequate viral suppressive concentrations, lopinavir
is co-administered with a low dose of ritonavir (lopinavir/ritonavir co-formulation is
approved at a dose of 400/100 mg twice daily and additionally at 800/200 mg once daily for
treatment-naïve patients in Europe and the United States [11, 12]). Ritonavir is a potent
inhibitor of ABCB1, CYP3A4 and CYP3A5 mediated metabolism and thereby increases the
exposure of lopinavir. Many PIs, have also been shown to activate the nuclear receptor
pregnane X receptor (PXR) [13], which is a key regulator of the expression of CYP3A4 [14]
and ABCB1 [15], and there is also some evidence that PXR regulates OATP1B1 expression
[16, 17]. Drug transporters, like OATP1B1, play a fundamental role in drug uptake
delivering the drug metabolic enzymes and facilitating clearance [5, 18]. The main purpose
of this study was to develop and validate a population PK model for boosted lopinavir, and
to quantify the influence of the SLCO1B1 521T>C (rs4149056) polymorphism, which has
been shown to affect lopinavir plasma concentrations [1, 19, 20].
Methods
Patients
A total of 375 HIV-positive patients on lopinavir/ritonavir 400/100 mg (tablets) based
regimens were included from the Liverpool Therapeutic Drug Monitoring Registry
(Liverpool, United Kingdom). Samples were taken at random time points post dosing,
plasma was obtained and stored at −80°C before analysis. All the patients had HIV viral
load <50 copies/mL at the time of sampling. Exclusion criteria included pregnancy,
undetectable plasma lopinavir concentrations (suggesting non-adherence to the regimen) and
concomitant use of known enzyme inducers. Of the patients included in the analysis, 82%
were male, median age was 40 (range 19–66), median weight was 72Kg (range 45–117).
Associations of SLCO1B1 polymorphisms with lopinavir plasma concentrations in this
cohort have previously been published [1].
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Lopinavir plasma concentrations and SLCO genotyping
Plasma obtained from blood samples was heat inactivated (58°C; 40 min) and lopinavir
concentrations were determined using a validated HPLC-MS/MS method as previously
described [21]. The lower limit of quantification of lopinavir was taken as the lowest point
on the standard curve (95 ng/mL). Intra-assay and inter-assay coefficients of variation at the
limit of quantification were between 5% and 7%, respectively. The Liverpool laboratory
participates in an external quality assurance scheme (KKGT, The Hague, The Netherlands).
The frequency of the minor alleles for SLCO1B1 521 (C) was 11%. This SNP was in
Hardy–Weinburg equilibrium as assessed by χ2 test of observed versus predicted genotype
frequencies. In total, 295 (78%) patients carried 521TT allele, 73 (20%) had 521CT and 7
(2%) patients had 521CC. Total genomic DNA was isolated using a GenElute Blood
Genomic DNA kit (Sigma-Aldrich, Poole, UK), according to manufacturer’s instructions.
Genotyping was carried out on 2ml of the final eluent (100ml) using a real-time qPCR-based
allelic discrimination assay as described previously [22]. All genotyping experiments were
performed in duplicate and contained negative controls (no template) and three positive
controls for each of the possible genotypes. Genotype was assigned only when both
duplicates were in agreement.
Population pharmacokinetic analysis
The pharmacokinetic model was developed using NONMEM® (version VI; Icon
Development Solutions, Ellicott City, MD, USA) installed under nmqual (Metrum institute)
[23]. Data processing and graphical analyses were carried out using Microsoft Office Excel
2007 for Windows (Microsoft Corporation, Redmond, WA, USA). The model-building
strategy was as follows. One- and two-compartment models with first- or zero-order
absorption without and with lag time were fitted to the data using the first-order conditional
method of estimation with interaction. Proportional, additive, and combined proportional
and additive error models were evaluated to describe residual variability. In the model,
residual variability was best described by a purely proportional structure. Interindividual
random effects were described by an exponential model: θi = θ×exp(ηi), where θi is the
pharmacokinetic parameter of the ith individual, θ is the average population value, ηi is the
interpatient random effect assumed to have a mean of zero and variance ω2. The minimal
objective function value (OFV; equal to −2log likelihood) was used as a goodness-of-fit
diagnostic with a decrease of 3.84 points corresponding to a statistically significant
difference between models (P=0.05, χ2 distribution, 1 degree of freedom). Residual plots
were also examined. Once the appropriate structural model was established, the following
covariates were explored: body weight, age, gender, and SLCO1B1 genotypes. Graphical
methods were used to explore the relationship of covariates with individual predicted
pharmacokinetic parameters. Each covariate was introduced separately into the model and
retained only if inclusion in the model produced a statistically significant decrease in OFV
of 3.84 (P ≤ 0.05) and was biologically plausible. A backward elimination step was then
carried out once all relevant covariates were incorporated, and covariates were retained if
their removal from the model produced a significant increase in OFV (>6.63 points; P ≤
0.01, χ2 distribution, 1 degree of freedom). Dichotomous and continuous variables, here
defined as X, were introduced into the model using the following parameterizations,
respectively:
1
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where TVCL is the typical value of lopinavir clearance (CL/F) of the population; in equation
1, θ0 is the value of CL/F for the individuals X=0 and θ1 is the relative difference in CL/F
for the individuals X=1. In equation 2, for example, θ0 is the typical CL/F at the median
body weight and θ1 is the change in CL/F per kg.
The effect on CL/F for variant genotype 521T>C was expressed as CL=CL0+θ1×HET
+θ2×HOM, where HET and HOM indicate genotypic status being equal to 1 for
heterozygous and homozygous individuals, respectively, and 0 for the wild-type patients.
CL0 is the typical value of CL/F for individuals carrying 521TT alleles.
Model qualification
To assess the stability and performance of the model, a visual predictive check was carried
out, and 1,000 data sets were simulated using the parameter estimates defined by the final
model with the SIMULATION SUBPROBLEMS option of NONMEM®. Data sets were
simulated for boosted lopinavir 400 mg twice daily. From the simulated data, 90%
prediction intervals (P5 to P95) were constructed and observed data from the original data
set were superimposed. If 90% of data points fell within the prediction interval, that was
indicative of an adequate model. In addition, in order to confirm the stability and robustness
of the model, a bootstrap re-sampling was used. Bootstrapping was performed with the
software package Perl-speaks-NONMEM 5.1 [24]. The median values and 90% CIs for the
parameter estimates were obtained from 200 bootstrap replicates of the original data set and
compared with the original population parameters.
External model qualification
External validation was performed for the final model based on qualitative and quantitative
evaluations of the predictive performance in an external data set of 42 observations from 6
patients that received lopinavir-based antiretroviral therapy. Two individuals had 521TC
genotype and four individuals 521TT. These patients were recruited from the Department of
HIV Medicine, Royal Free NHS Trust, London, and the samples were analyzed by the
Liverpool laboratory. The fixed and random estimates obtained from the model were used to
predict individual lopinavir concentrations, which were plotted and compared with actual
concentration values. Mean prediction error and its 95% confidence interval (CI) was
calculated as a measure of bias.
Simulation of the genetic effect on lopinavir at different doses
To investigate the effect of genetics on lopinavir concentration at the end of the dosing
interval (Ctrough), simulated pharmacokinetic data for lopinavir, stratified for SLCO1B1
genotype, were generated. Ninety percent prediction intervals of the simulated
concentrations for each category were calculated. Additionally, 1000 individuals were
simulated using the fixed and random effects of the final model that we previously published
[25] at a lopinavir/ritonavir dose of 200/50 mg twice daily and also to evaluate a missed
dose during a twice daily regimen (dosed 400/100 mg twice daily, evening dose missed, it
will be referred to as 400/100 mg once daily); individuals were simulated considering
different genetics using the estimated effect of SLCO1B1 521T>C on CL/F found in this
study. The simulation was carried out using a sequential model with a direct concentration-
dependent relationship of the form of CL/FLPV = CL0/FLPV * [1 − ((IMAX * CRTV) / (IC50 +
CRTV))], where CL/FLPV is lopinavir clearance, CL0/FLPV is lopinavir clearance in the
absence of ritonavir, CRTV is the ritonavir plasma concentration at each time point, IMAX is
the maximum inhibitory effect of ritonavir on CL/FLPV and IC50 is the CRTV producing 50%
of the IMAX.
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Results
Data from 594 plasma samples were collected from the patient population. The lopinavir
plasma concentrations were in a range of 0.114 to 22.432 mg/L. An external data set of 42
samples from 6 HIV positive individuals was used to validate the model, in addition to an
internal validation. A 1-compartment model described the data better than a 2-compartment
model and therefore was kept as the base model. The inter-individual variability was
supported only for apparent clearance. The introduction of a lag time did not significantly
improve the fit. In the basic model the mean population estimates for CL/F, apparent volume
of distribution (V/F) and absorption constant (ka) were 5.7 L/h, 45.5 L and 0.2 h,
respectively.
A total of four covariates (weight, age, gender and SLCO1B1 521T>C) were analysed using
a stepwise forward-backward elimination. CL/F significantly (P<0.001) correlated with two
covariates: weight and SLCO1B1 521T>C. In the forward inclusion age and gender were
also selected. However, during the backward elimination these covariates did not meet the
inclusion criteria and therefore were excluded from the final model. The mean population
estimate for CL/F was 5.67 L/h; the final covariate model is detailed in table 1. Inclusion of
body weight resulted in an improvement of the goodness of the fit (ΔOFV = 20.5, P <
0.001), a slight decrease in inter-individual variability of 1% and CL/F increased by 0.5 L/h
with body weight increases of 10 kg.
The inclusion of this polymorphism decreased the OFV by 15 units (P < 0.001) and the IIV
by 2% compared with the base model. In subjects who were heterozygous for 521TC CL/F
decreased by 0.8 L/h, and in homozygotes the model showed a more significant decrease in
CL/F of 2.1 L/h. The diagnostic plots for the final model showed that predicted and
observed data were in agreement (figure 1). The individual conditional weighted residuals
did not reflect any particular systematic trends.
Internal model qualification
A 90% prediction interval was generated from 1000 simulations for boosted lopinavir 400
mg twice daily, with the covariate values of those individuals used in the model building
process. Observed data from patients used in the model-building process were superimposed
onto the prediction interval. Of 323 plasma concentrations, 4.3% were above P95 and 4.6%
were below P5, which suggests that overall the final model performed adequately (figure 2).
In addition, from the original data set, 200 bootstrap replicate data sets were generated and
used to evaluate the stability of the final model. The median values of the parameter
estimates from the bootstrapping were very similar to the mean population estimates for the
final model (table 1). The 90% confidence interval (CI) for the parameter estimates obtained
from the bootstrap procedure revealed adequate estimation of the pharmacokinetic
parameters for both fixed and random effects and robustness of the final model.
External model qualification
External validation of the model was performed in a total of 42 observations from 6 patients.
Individual lopinavir predictions versus actual concentrations in the model validation dataset
are shown in figure 2. The small number of patients for the external validation can be
considered a limitation. However, the performance of the individual predictions was
satisfactory, with a bias (95% CI) of 2.1% (−1.1 to 5.3).
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Simulation of the impact of genetics on lopinavir at different doses
In order to evaluate the clinical impact of the pharmacogenetic factors, simulated
concentration-time courses of lopinavir (400mg twice daily) at steady-state were performed.
The simulations were performed separately with a population of individuals homozygous for
the common alleles (521TT) and with the variant alleles 521 TC and 521CC (figure 3). The
predicted 95th percentile of lopinavir (median [P5 –P95] 400 mg twice daily) trough
concentrations (Ctrough) for individuals carrying alleles 521TT, 521TC and 521CC were: 5.0
(1.1-13.2), 5.11 (1.4-15.6) and 7.4 (2.0-22.1), respectively.
The effect of a missing dose on patients stable on 400/100 mg twice daily was also
evaluated, mean lopinavir Ctrough from simulated concentrations of lopinavir/ritonavir
400/100 mg once daily for individuals carrying the 521CC SNP were higher than the alleged
minimum effective concentration in treatment naive patients (MEC) of 1 mg/L (1.23 mg/L,
95%CI 1.16-1.29). The number of individuals 521CC below the MEC was 40% of the total
simulated population. The simulations were repeated using 521TC individuals and the
results of mean lopinavir Ctrough were significantly below the MEC (0.43 mg/L, 95%CI
0.39-0.46), the number of individuals below the MEC was 83% of the total simulated
population. A second series of simulations were carried out with a reduction of dose of
lopinavir/ritonavir to 200/50 mg twice daily. Individuals with 521CC and 521TC achieved a
mean Ctrough of 2.36 mg/L (95%CI 2.32-2.41) and 1.49 (95%CI 1.46-1.53), respectively
(figure 4). The number of individuals below the MEC was 2% and 18%, respectively.
Discussion
A model has been developed and validated to describe lopinavir pharmacokinetics in HIV-
infected individuals and used to quantify the influence of SLCO1B1 521T>C on CL/F.
Simulations of lopinavir/ritonavir 200/50 mg twice day and 400/100 mg once daily
associated with the polymorphism 521T>C generated a lopinavir mean Ctrough above the
MEC (1 mg/L) for trreatment-naive patients. The simulations were performed using a
sequential model, which was developed previously [25], and allowed incorporation of the
effect of both ritonavir and SLCO1B1 521T>C on lopinavir plasma concentrations.
OATP1B1 is predominantly expressed at the sinusoidal membrane of hepatocytes. The
521T>C polymorphism has been consistently associated with reduced transport activity in
vivo [6, 19], leading to reduced uptake by hepatocytes and higher plasma concentrations of
different classes of therapeutic drugs, such as hypocholesterolaemic statins and meglitinide
analogue hypoglycaemic agents [19, 26]. Recently, we identified lopinavir as a substrate of
SLCO1B1 and showed that a variant in SLCO1B1 (rs4149056) was associated with
impaired transport activity, and therefore increased lopinavir plasma concentrations. The
model that best described lopinavir pharmacokinetics was a one-compartment model with
first-order absorption and elimination. Although the V/F was slightly under estimated, the ka
and CL/F were consistent with values previously published [20, 25, 27]. The dataset
included sparse data from a TDM cohort and only a limited number of samples in the
absorption phase. This could explain the lack of inter-individual variability for ka and may
also affect the determination of inter-individual variability for V/F.
Body weight was the only demographic covariate significantly related to CL/F, which
increased by 8.8% with a body weight increase of 10 kg. The inclusion of SLCO1B1
genetics also improved the model fit. The effect of the 521CC genotype was particularly
significant, decreasing CL/F by 37%, and there was a gene–dose effect with 521TC
decreasing CL/F by 14% compared with the 521TT genotype.
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There are limited data on the interaction between PIs and the SLCO1B1 521T>C
polymorphism [6]. Recently, Lubomirov et al. [6, 20] incorporated population PK and
521T>C and showed a decrease in CL/F consistent with our finding for 521TC (CL/F 14%
decrease), but the change in CL/F was less for 521CC (21% vs 37%). Kohlrausch et al. [19]
reported an increment in lopinavir Ctrough of 49% in individuals carrying 521CC; the
average of the simulated Ctrough in our study showed an increase of 57% compared with
521TT. In these studies the number of individuals carrying 521CC was limited, therefore to
better define the impact of this SNP further studies are warranted. One of the limitations of
the present study is the lack of ethnicity data and this also has implications for the Hardy
Weinburg Equilibrium calculations. However, previous studies did not observe an
association between trough concentrations of lopinavir and ritonavir and ethnicity [19, 20,
25]. The allele frequency of this polymorphism is comparable between Hapmap Asian
populations (e.g. 14% in Han Chinese and 12% in Japanese) and the Caucasian population
(15%). However, it is considerably lower in some African Hapmap populations (E.g. 2% in
Yoruban and 1% Luhya) and therefore, it should be noted that this population PK analysis
may not be universally applicable. The present results must also be interpreted in the context
of the inherent limitations of TDM cohorts resulting from selection bias and a lack of
information on factors such as ethnicity. However, given these limitations, TDM data
represents a potentially valuable resource for hypothesis generation in pharmacogenetic
studies. Nonetheless, as with any pharmacogenetic association, the findings should be
validated in other cohorts.
In order to simulate different doses and evaluate the possible clinical impact of the
SLCO1B1 521T>C SNP, the effect of ritonavir had to be taken in account. The data used in
this study, did not include the respective ritonavir concentrations. Thus, an external model,
which we have recently published, was used to simulate lopinavir and ritonavir
concentrations, in order to consider the effect of ritonavir on lopinavir concentrations over
time. In the simulation the effect of the 521T>C, which was determined in the present study,
was included. This effect was evaluated only on lopinavir plasma concentrations, since the
previous study indicated no correlation between 521T>C polymorphism and ritonavir
plasma concentrations [1]. Interestingly, the results indicated that the mean Ctrough
concentrations for lopinavir/ritanovir 200/50 mg twice day, in heterozygous and
homozygous individuals were above the MEC of 1 mg/L for treatment-naive patients.
Additionally, for the missed dose simulation (400/100 mg once daily), the simulated Ctrough
at 24 hours had a lopinavir mean Ctrough concentration above the MEC for C homozygous
individuals.
Modelling and simulation incorporating genetics alone may help to inform future clinical
studies and provide an insight into whether dose optimization of lopinavir/ritonavir is
possible considering the genetic constitution of an individual. A recent clinical study [28]
showed that therapeutic plasma concentrations of lopinavir can be achieved with 200/150
mg of lopinavir/ritonavir twice daily and that the majority of volunteers were above the
lopinavir MEC following 200/50 mg twice daily. Dose adjustment based on SLCO1B1
521T>C or a panel of drug disposition SNPs may be considered as a dosing strategy with the
potential to reduce both costs and toxicity However, these data are based purely on
pharmacokinetic analysis and the effect of the alternate lopinavir/ritonavir dose on viral
suppression requires further investigation.
Acknowledgments
This work was supported by programme grant funding from the Wellcome Trust (reference number 083851/Z/07/
Z.)
Schipani et al. Page 7
Antivir Ther. Author manuscript; available in PMC 2012 October 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
References
1. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE,
Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A. HIV protease inhibitors are substrates for
OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by
SLCO1B1 polymorphisms. Pharmacogenetics and genomics. 2010; 20:112–120. [PubMed:
20051929]
2. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. Role of organic anion-transporting
polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem
excretory pathway for foetal bilirubin. Biochem J. 2003; 371:897–905. [PubMed: 12568656]
3. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, Meier PJ.
Molecular and functional characterization of an organic anion transporting polypeptide cloned from
human liver. Gastroenterology. 1995; 109:1274–1282. [PubMed: 7557095]
4. Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 Polymorphism and Oral Antidiabetic Drugs.
Basic Clin Pharmacol Toxicol. 2010; 107:775–781. [PubMed: 20406215]
5. Kalliokoski, a; Niemi, M. Impact of OATP transporters on pharmacokinetics. British journal of
pharmacology. 2009; 158:693–705. [PubMed: 19785645]
6. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1 : a genetically
polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;
63:157–181. [PubMed: 21245207]
7. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry
C, Perno CF. Therapeutic drug monitoring in HIV infection: current status and future directions.
AIDS. 2002; 16(Suppl 1):S5–37. [PubMed: 12035820]
8. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in
relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999; 13:473–478.
[PubMed: 10197375]
9. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D,
Beijnen JH, Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved
virological response in HIV-1-infected individuals. AIDS. 2001; 15:1089–1095. [PubMed:
11416710]
10. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can
predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS.
2001; 15:71–75. [PubMed: 11192870]
11. [15 June 2011, date last accessed] Kaletra® (lopinavir/ritonavir) tablets and oral solution US
Prescribing Information. http://www.rxabbott.com/pdf/kaletratabpi.pdf
12. [15 June 2011, date last accessed] Kaletra® 200 mg/50 mg film-coated tablets Summary of
Product Characteristics. http://www.medicines.org.uk/emc/medicine/18442
13. Schipani A, Siccardi M, D’Avolio A, Baietto L, Simiele M, Bonora S, Novoa S Rodriguez, Cuenca
L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod
HL, Davies G, Khoo S, Back DJ, Di Perri G, Owen A. Population pharmacokinetic modeling of
the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir
clearance. Antimicrob Agents Chemother. 2010; 54:5242–5250. [PubMed: 20921307]
14. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology.
2000; 153:1–10. [PubMed: 11090943]
15. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of
intestinal MDR1 by rifampin. J Biol Chem. 2001; 276:14581–14587. [PubMed: 11297522]
16. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of
sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-
sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006; 34:1756–1763.
[PubMed: 16837569]
17. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M.
Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic
liver injury. Proc Natl Acad Sci U S A. 2005; 102:2063–2068. [PubMed: 15684063]
Schipani et al. Page 8
Antivir Ther. Author manuscript; available in PMC 2012 October 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
18. Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT.
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-
tumor barrier. Cancer Res. 2005; 65:11419–11428. [PubMed: 16357150]
19. Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1
polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
British journal of clinical pharmacology. 2010; 69:95–98. [PubMed: 20078617]
20. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P,
Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd La, Csajka
C, Telenti A. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral
agent lopinavir coformulated with ritonavir. Pharmacogenetics and genomics. 2010; 20:217–230.
[PubMed: 20139798]
21. Dickinson L, Robinson L, Tjia J, Khoo S, Back D. Simultaneous determination of HIV protease
inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in
human plasma by high-performance liquid chromatography-tandem mass spectrometry. J
Chromatogr B Analyt Technol Biomed Life Sci. 2005; 829:82–90.
22. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects
the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16:873–879. [PubMed:
17108811]
23. Knebel, BBT.; Gibiansky, L.; Hane, JT.; Gastonguay, MR. Population Approach Group Europe.
NMQual: A Tool to Automate Installation and Facilitate Qualification of NONMEM.
24. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM
related programming. Comput Methods Programs Biomed. 2004; 75:85–94. [PubMed: 15212851]
25. Dickinson L, Boffito M, Back D, Else L, von Hentig N, Davies G, Khoo S, Pozniak A, Moyle G,
Aarons L. Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy
volunteers and assessment of different dosing strategies. Antimicrob Agents Chemother. 2011;
55:2775–2782. [PubMed: 21422211]
26. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto
KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major
determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005; 77:468–478. [PubMed:
15961978]
27. Moltó J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negredo E, Costa J, Domingo P, Clotet B,
Valle M. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-
infected adults. Clinical pharmacokinetics. 2008; 47:681–692. [PubMed: 18783298]
28. Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A. Pharmacokinetics of
atazanavir / ritonavir once daily and lopinavir / ritonavir twice and once daily over 72 h following
drug cessation. Antivir Ther. 2008; 13:901–907. [PubMed: 19043924]
Schipani et al. Page 9
Antivir Ther. Author manuscript; available in PMC 2012 October 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Goodness of fit plots for the final pharmacokinetic model
(A) population predictions of lopinavir vs. observed concentrations, (B) individual
predictions of lopinavir vs. observed concentrations. The continuous line shows the line of
unity and the broken line shows the line of regression. (C) Conditional weighted residuals
vs. time post-dose, the continuous line shows the line at ordinate values zero.
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Figure 2.
(A) 90% prediction intervals determined from simulated data of boosted lopinavir 400 mg
twice daily. The median population prediction is shown as a continuous line and the 90%
prediction interval is shown as a broken line. (B) Goodness of-fit plots of the validation of
the lopinavir model performed with an external data-set in a total of 42 observations from 6
patients. The broken line is the line of regression of the observed concentrations, and the
continues black line is the line of identity.
Schipani et al. Page 11
Antivir Ther. Author manuscript; available in PMC 2012 October 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Steady-state lopinavir mean plasma concentration predictions for lopinavir/ritonavir
400/100 mg twice daily determined from simulated data in individuals with different genotypes
The continuous line describes mean population prediction for individuals carrying the
521CC genotype. The thin dotted line describes mean population prediction for individuals
carrying the 521TC genotype. The dashed line describes mean population prediction for
individuals carrying the 521TT genotype. The horizontal continuous line is at an ordinate
value of 1 mg/L (proposed minimum effective concentration).
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Figure 4. Lopinavir mean plasma concentration predictions determined from 1000 simulations
(A) Prediction for lopinavir/ritonavir 400/100 mg once day for individuals with the 521CC
and 521TC genotype. (B)Prediction for lopinavir/ritonavir 200/50 mg regimen twice a day
for individuals with the 521CC and 521TC genotype. Grey areas represent the 95% CI. The
horizontal continuous line is at an ordinate value of 1 mg/l (proposed minimum effective
concentration).
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Table 1
LPV parameter estimates and standard errors obtained from the final population pharmacokinetic model.
Basic Model Final Model
Bootstrapped median (90% CI)
in the final modelParameter Estimate(RSE %)
Estimate
(RSE %)
CL/F (L/h) 5.29 (3) 5.67 (4) 5.67 (5.22, 6.12)
V/F (L) 42.4 (17) 45.5 (14) 44.30 (16.66, 74.33)
ka (h−1) 0.18 (14) 0.20 (6) 0.19 (0.07, 0.32)
IIV CL/F % 40 (38)a 37 (44)a 36 (29.5, 43.9)
Factor associated with BW on LPV CL/F - 0.0457 (22) 0.046 (0.025, 0.066)
Factor associated with T/C on LPV CL/F - −0.791 (36) −0.757 (−1.34, −0.23)
Factor associated with C/C on LPV CL/F - −2.09 (29) −1.97 (−3.28, −0.89)
Proportional residual error, % 32.2 (12) 33.1 (13) 33.3 (25, 44)
a
Relative standard errors (RSEs), defined as (SEestimate/estimate)×100, of the CV, taken as √(SE/estimate) and expressed as percentage. BW: body
weight; CL/F: apparent oral clearance; IIV: interindividual variability; LPV: lopinavir; ka: absorption rate constant; V/F: apparent volume of
distribution.
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